\n<\/p>\n
Abortion provider Carafem\u2019s phones were ringing nonstop over the weekend after a US federal appeals court reinstated a nationwide requirement that the drug mifepristone, one of two pills used for a medication abortion, must be obtained in person. The decision, handed down on Friday, left patients unsure if they could gain access to their treatment through telehealth. \u201cPeople are afraid, and they\u2019re angry,\u201d says Carafem\u2019s chief operations officer, Melissa Grant. \u201cI had people contact us saying, This can\u2019t be true<\/em>. Do you still have the medication available? Can\u2019t you just give it to me?<\/em> They were bargaining.\u201d<\/p>\n With the restriction in place, Carafem quickly pivoted to a backup approach. Instead of prescribing the two-drug protocol typical for a medication abortion\u2014mifepristone, which blocks progesterone and prevents the pregnancy from progressing, and then misoprostol, which causes the uterus to contract\u2014the organization began prescribing misoprostol on its own. While slightly less effective than the dual-pill option, it\u2019s been widely used in the past. \u201cWe feel comfortable prescribing it,\u201d says Grant.<\/p>\n Some Planned Parenthood clinics also pivoted to the misoprostol-only regimen this weekend. \u201cPlanned Parenthood providers are doing everything they can to make sure patients know that medication abortion is still safe, legal, and available,\u201d says Danika Severino, vice president of care and access at Planned Parenthood Federation of America.<\/p>\n On Monday, the Supreme Court offered a temporary reprieve, pausing the appeals court ruling for a week. The measure allows patients to once again get mifepristone through virtual clinics at least until May 11, when SCOTUS will take another look at the case. Carafem and Planned Parenthood say they are prepared to shift back to misoprostol-only if necessary. Other providers, including the digital abortion clinic HeyJane, have confirmed that they will also take that approach if necessary.<\/p>\n Mifepristone was developed in the 1980s in France and has been extensively studied for safety and efficacy. It was approved by the Food and Drug Administration in 2000. Under President Joseph Biden, the FDA first allowed the drug to be obtained by mail instead of in person in April 2021, during the Covid-19 pandemic. The agency permanently lifted the in-person dispensing requirement in 2023.<\/p>\n After the Supreme Court overturned Roe v. Wade<\/em> in 2022, ending the constitutional right to an abortion, medication abortion via telehealth became a more sought-after option, especially for patients in states that adopted abortion restrictions. Approximately one in three abortions that took place in the first half of 2025 used abortion pills obtained through telehealth, according to public health nonprofit Plan C.<\/p>\n Access to mifepristone has become the next major battleground in reproductive health, with anti-abortion politicians and lobbyists seeking to reinstate in-person dispensing requirements on the drug and, by doing so, make medication abortion harder to obtain.<\/p>\n After conflicting legal rulings in 2023 sparked confusion over whether mifepristone would be available from virtual clinics, some of them planned to temporarily shift to offering misoprostol-only medication abortions. Some virtual clinics have offered single-pill options even before that. Carafem offered misoprostol-only medication abortions beginning in 2020, in an effort to provide patients with options for virtual care during the early days of Covid.<\/p>\n Originally developed to treat gastric ulcers, misoprostol has been used for medication abortion since the late 1980s. It remains the primary method of medication abortion in many parts of the world where access to mifepristone is limited.<\/p>\n \u201cMifepristone and misoprostol are both very safe medications, and in general, having mifepristone increases the efficacy and decreases complication rates of medication abortion,\u201d says Rachel Jensen, a fellow with the American College of Obstetricians and Gynecologists, which endorses the misoprostol-only protocol when mifepristone isn\u2019t available. The single-drug regimen is also endorsed by the World Health Organization, the Society of Family Planning, and the National Abortion Federation.<\/p>\n<\/div>\n